Open Access Complementary

Scientist Turned Entrepreneur to Tackle Diabetes: Novel Therapy in the Making

Arjun Jain*

Judge Business School, University of Cambridge, Cambridge, United Kingdom

Corresponding Author

Received Date:July 01, 2019;  Published Date:July 02, 2019


The following article discusses the current status of a novel tool, ET-traps, which is an Fc fusion protein that may become a potential therapeutic for use in diabetes, as well as various other diseases associated with pathologically elevated endothelin-1 levels. The ET-traps have a very high and fast association to their target (endothelin-1) and a very slow dissociation once bound to their target.

Dr Arjun Jain, Founder and Managing Director of ET-traps Limited, reminisced about his journey from scientist to entrepreneur.

Keywords: Endothelin-1; ET-traps; Diabetes; Cardiovascular diseases; Neurodegenerative disorders; Cancers

Signup for Newsletter
Scroll to Top